Comparative Pharmacology
Head-to-head clinical analysis: HYDROMOX R versus NAQUIVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROMOX R versus NAQUIVAL.
HYDROMOX R vs NAQUIVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide-like diuretic that inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
NAQUIVAL (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing electrolyte reabsorption and increasing urine output, thereby lowering blood pressure and reducing edema.
Oral, 50 mg once daily, increased to 100 mg once daily if needed.
Adults: 0.1 mg/kg IV bolus, then 0.1 mg/kg/hour continuous IV infusion, titrated to clinical response. Maximum 0.5 mg/kg/hour.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 14-16 hours (healthy adults). Extended to 26-35 hours in heart failure or hepatic cirrhosis due to reduced clearance.
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30% as unchanged drug and metabolites.
Renal: 50-60% as unchanged drug; fecal: <10% (biliary); remainder as metabolites (80% renal, 10% fecal).
Category C
Category C
Thiazide Diuretic Combination
Thiazide Diuretic Combination